ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
Public ClinicalTrials.gov record NCT05446298. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients With Platinum Resistant Ovarian Cancer (PROC)
Study identification
- NCT ID
- NCT05446298
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- OncoC4, Inc.
- Industry
- Enrollment
- 58 participants
Conditions and interventions
Conditions
Interventions
- ONC-392 Drug
- Pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 21, 2022
- Primary completion
- Aug 29, 2026
- Completion
- Aug 29, 2026
- Last update posted
- Apr 12, 2026
2022 – 2026
United States locations
- U.S. sites
- 21
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cancer Treatment Centers of America, Phoenix. 403 | Goodyear | Arizona | 85338 | — |
| Honor Health, USOR, 406 | Phoenix | Arizona | 85082 | — |
| Nuvance Health System, 401 | Danbury | Connecticut | 06856 | — |
| Baptist MD Anderson Cancer Center, 404 | Jacksonville | Florida | 32207 | — |
| Sudarshan Sharma, MD. LTD. 414 | Hinsdale | Illinois | 60521 | — |
| Cancer Treatment Centers of America, Chicago. 410 | Zion | Illinois | 60099 | — |
| Northwest Cancer Centers - Dyer, IN - USOR, 422 | Dyer | Indiana | 46311 | — |
| Baptist Health Lexington, 407 | Lexington | Kentucky | 40503 | — |
| Norton Cancer Institute - St. Matthews, 416 | Louisville | Kentucky | 40207 | — |
| Willis-Knighton Physician Network / Gynecologic Oncology Associates, 409 | Shreveport | Louisiana | 71103 | — |
| Minnesota Oncology Hematology, P. A. - USOR, 421 | Maplewood | Minnesota | 55109 | — |
| Center of Hope, 413 | Reno | Nevada | 89511 | — |
| The Valley Hosptial, Inc. 411 | Ridgewood | New Jersey | 07450 | — |
| Women's Cancer Care Associates, LLC. 405 | Albany | New York | 12208 | — |
| The Ohio State University James Cancer Center, 412 | Columbus | Ohio | 43210 | — |
| Oncology Associates of Oregon, P. C. - USOR. 419 | Eugene | Oregon | 97401 | — |
| Texas Oncology, P. A. - Austin, USOR. 417 | Austin | Texas | 78731 | — |
| Texas Oncology, P.A., Fort Worth - USOR. 420 | Fort Worth | Texas | 76104 | — |
| Texas Oncology, P. A. Woodlands - USOR, 418 | The Woodlands | Texas | 77380 | — |
| Texas Oncology - Northeast Texas - USOR, 423 | Tyler | Texas | 75702 | — |
| Medical College of Wisconsin, 408 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05446298, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05446298 live on ClinicalTrials.gov.